Brokerages Set Evotec AG (NASDAQ:EVO) PT at $7.00

Evotec AG (NASDAQ:EVO) has been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $7.00.

A number of equities research analysts have recently weighed in on the company. HC Wainwright assumed coverage on Evotec in a research report on Wednesday, April 15th. They set a “buy” rating and a $7.00 target price for the company. Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Berenberg Bank assumed coverage on Evotec in a report on Tuesday, February 3rd. They set a “buy” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th.

Evotec Trading Up 2.5%

Shares of Evotec stock opened at $3.23 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.07 and a quick ratio of 1.99. The firm has a 50 day simple moving average of $2.92 and a 200 day simple moving average of $3.27. Evotec has a fifty-two week low of $2.31 and a fifty-two week high of $4.80.

Evotec (NASDAQ:EVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $297.02 million for the quarter. Evotec had a negative return on equity of 12.40% and a negative net margin of 13.13%. On average, analysts anticipate that Evotec will post -0.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Evotec

Several large investors have recently bought and sold shares of EVO. Marshall Wace LLP bought a new stake in shares of Evotec in the 4th quarter valued at $40,000. Valeo Financial Advisors LLC bought a new position in Evotec during the second quarter worth about $43,000. SmartHarvest Portfolios LLC bought a new position in Evotec during the first quarter worth about $44,000. BNP Paribas Financial Markets grew its stake in Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after acquiring an additional 4,600 shares during the period. Finally, Thrivent Financial for Lutherans acquired a new position in Evotec in the third quarter valued at about $53,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.